Boron neutron capture therapy (BNCT) is a method of cancer therapy with a simple idea behind it. Positioning a certain amount of 10B-enriched boron-containing compounds into tumor cells with subsequent irradiation of the tumor tissue by thermal or epithermal neutrons causes tumor damage and death. The mechanism of the tumor cell damage during BNCT is based on the capture-fission reaction between the boron-10 nucleus and a neutron resulting in an a-particle release inside the cell. A successful BNCT therapeutic agent must obey several requirements, most importantly it should (1) selectively accumulate in tumor cells, (2) show certain levels of tumor-to-blood concentration ratios (3 and higher), and (3) provide the therapeutic concentration of 10B in tumor cells (at least 20 μg of 10B/g of tumor).
During the last 60 years, BNCT application in medicine was slowed down by two main factors. The first was almost exclusive concentration of the efforts on studying BNCT effect for brain tumors such as Glioblastoma multiforme which is very difficult to treat . The second factor was the use of only two compounds for clinical trials: boronophenylalanine (BPA) and sodium borocaptate (BSH, thiol derivative of the [B12H12]2- polyhedral borane anion). Although both compounds did not perform very well, they did not require any special delivery techniques and could be administered in water solutions intravenously. Unsatisfactory results of first clinical studies inhibited the development of BNCT for decades.
The new era of BNCT started in the 1990's when a novel approach to the delivery of boron compounds (different from BPA and BSH) into tumors in hydrophilic cores of liposomes was suggested . The liposome formulations were later improved by incorporating boron-containing molecules both into the lipid bilayer and into the hydrophilic core. The range of boron-containing compounds used for the liposome bilayer formation/incorporation includes amphiphilic nido-carboranes [3,4], nido-carborane and polyhedral borane analogs of lipids , carborane- and metallacarborane-substituted cholesterols and cholesterol mimics [6-8]. Compounds used for incorporation into the hydrophilic core include BSH, salts hydrolytically stable boranes such as Na3[B20H17NH3], and nido-carboranes.
After nanomaterials became a 'hot topic' in 2000's, a new approach to the BNCT agents delivery via nanoparticles started to develop. Three major types of delivery vehicles were created. The first type contains a BNCT-neutral core containing the therapeutic agent on the periphery. The most common materials for the core formation are gold  and silica . The periphery of the core, in the case of gold nanoparticles, was functionalized by closo-carboranes and connected to the core by organic linkers. For the mesoporous silica nanoparticles, the therapeutic agent was incorporated in solution into the pores of the nanoparticles. The core of the second type nanoparticles contains therapeutic agent while the periphery contains targeting groups or groups increasing solubility, such as PEGs. The core may be constructed from boron carbide , elementary boron , borosilicate glass , boron phosphate , or boron-containing organic polymer . The third kind of nanoparticles for BNCT contains therapeutic agent both in the core and on the periphery of the particle. Unimolecular nanoparticles of this type (closomers) are constructed based on a [B12(OH)12]2- core functionalized by twelve nido-carboranes using alkyl linkers .
Another type of nanomaterial carriers for BNCT applications started developing only very recently. These are single-wall carbon nanotubes  and silicon nanowires  covered with physisorbed ortho-carborane and BSH, respectively.
It would be wrong to conclude that all problems of BNCT were solved with the development of new boron delivery methods and materials. The main problem of the BNCT as a method is lack of clinical studies of the new materials. Most of the modern papers on BNCT report 'potential' BNCT agents; a lot of papers are purely synthetic and don't even include cell studies. And it seems that in some cases the abbreviation BNCT may become a 'golden ticket' for authors who just want to publish their study without intent to continue.
In spite of the named problems, there are positive moments in the recent development of BNCT. First, many different cancer models (not just one) are being studied such as head and neck cancers, colorectal cancer, melanoma, small-cell lung cancer, breast cancer and others. Second, BNCT studies which started in the 1950's as an American project nowadays are being carried out in many other countries of the world: Japan, Canada, UK, Argentina, Sweden, Italy, Finland, Netherlands, and Russia. Unfairly forgotten for many years, recently BNCT started an explosive development incorporating advances in chemistry, biology, medicine, and nuclear technology.
Hopefully, it will not take another sixty years for BNCT to become a routine clinical method.